How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide

Efstathios Kastritis; Meletios A Dimopoulos

doi:10.1080/10428190701742530

Abstract

1 min read

Thalidomide and lenalidomide are both immunomodulatory drugs with well established activity in all phases of multiple myeloma (MM) treatment. Phase II and III trials have proven the superiority of ...

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2013

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

Evangelos Terpos, Kanellias, Christoulas, Efstathios Kastritis, Meletios A Dimopoulos

Article2006

Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma

M. Wang, Robert Knight, Meletios A Dimopoulos, David S. Siegel, S. Vincent Rajkumar, Thierry Façon, Zhinuan Yu, J. Zeldis, Marta Olesnyckyj, D. Weber

Article2019

Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma

Ioannis Ntanasis‐Stathopoulos, Evangelos Terpos, Meletios A Dimopoulos

Article2008

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Michael Wang, Meletios A Dimopoulos, Christine Chen, María Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, Donna M. Weber

Article2005

Thalidomide and immunomodulatory drugs in the treatment of cancer

Aristotle Bamias, Meletios A Dimopoulos